Send us Feedback

AMAG Pharmaceuticals (AMAG)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
UPDATE: Ladenburg Thalmann Upgrades AMAG Pharmaceuticals to Buy
Benzinga  May 17  Comment 
Ladenburg Thalmann has published a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and has upgraded the company from Neutral to Buy based on valuation. In the report, Ladenburg Thalmann writes, "In essence, despite our view that Feraheme...
AMAG (AMAG) Shares Collapse as Board Quietly Abandons Active Sale Process
StreetInsider.com  May 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AMAG+%28AMAG%29+Shares+Collapse+as+Board+Quietly+Abandons+Active+Sale+Process/7425087.html for the full story.
UPDATE: Ladenburg Thalmann Downgrades AMAG Pharmaceuticals; Removes PT
Benzinga  May 10  Comment 
According to a research report published this morning, Ladenburg Thalmann has downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Buy to Neutral and removed its $19 PT. Ladenburg Thalmann commented in the report, "Our prior AMAG rating had been...
Incline Therapeutics Announces Appointment of John Tucker as Chief Commercial Officer
PR Newswire  May 10  Comment 
REDWOOD CITY, Calif., May 10, 2012 /PRNewswire/ -- Incline Therapeutics, Inc., a hospital-focused specialty pharmaceutical company, announced today the appointment of John Tucker as Senior Vice President and Chief Commercial Officer. Mr. Tucker has
AMAG Pharmaceuticals Appoints William Heiden as President and Chief Executive Officer
Benzinga  May 9  Comment 
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the appointment of William K. Heiden as president and chief executive officer, effective May 14, 2012. Mr. Heiden, age 52, has also been appointed to the company's board of directors. AMAG...
AMAG Pharmaceuticals Announces First Quarter 2012 Financial Results
Business Wire  May 1  Comment 
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical company focused on the development and commercialization of Feraheme® (ferumoxytol) Injection for intravenous (IV) use to treat iron deficiency anemia (IDA), today reported
Potential AMAG Pharmaceuticals (AMAG) Trade Targets 10.08% Return
Market Intelligence Center  Apr 27  Comment 
AMAG Pharmaceuticals (NASDAQ: AMAG) closed Thursday's trading session at $16.02. In the past year, the stock has hit a 52-week low of $12.65 and 52-week high of $19.62. AMAG Pharmaceuticals (AMAG) stock has been showing support around $15.57 and...
AMAG Pharmaceuticals, Inc. to Host Conference Call on May 1, 2012 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2012
Business Wire  Apr 24  Comment 
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2012 after the U.S. financial markets close on Tuesday, May 1, 2012. The announcement will be followed
AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease
Business Wire  Apr 20  Comment 
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron
AMAG Pharmaceuticals (AMAG) Showing Bearish Technicals But Could Break Through $16.23 Resistance
Market Intelligence Center  Apr 12  Comment 
AMAG Pharmaceuticals (NASDAQ: AMAG) closed Wednesday's trading session at $15.86. In the past year, the stock has hit a 52-week low of $12.65 and 52-week high of $19.62. AMAG Pharmaceuticals (AMAG) stock has been showing support around $15.35 and...




RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 
TOP CONTRIBUTORS
Sr. Director
Grant Zeng
www.zacks.com

Amag Pharmaceuticals Inc., formerly known as Advanced Magnetics Inc., develops and markets superparamagnetic iron oxide nanoparticles used in pharmaceutical products. The company is dedicated to the development and commercialization of its proprietary nanoparticle technology for use in therapeutic iron compounds to treat anemia, as well as imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company has two approved products, Feridex IV and GastroMARK, which are marketed primarily in the U.S. and Europe. Feridex IV is a liver contrast agent, and GastroMARK is an oral contrast agent used for delineating the bowel in MRI. The company has two primary product candidates, Ferumoxytol and Combidex. Ferumoxytol is in phase III multi-center clinical trials for use as an iron replacement therapeutic in chronic kidney disease patients, whether or not on dialysis. Combidex is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging (MRI) to aid in the differentiation of cancerous from normal lymph nodes.

Amag Pharmaceuticals was incorporated in Delaware in 1981 and is based in Cambridge, Massachusetts.




References

Retrieved from "http://www.wikinvest.com/stock/AMAG_Pharmaceuticals_(AMAG)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki